TrialJAMA oncology2017

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Joanne B Weidhaas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.